End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
12,890 ARS | +2.77% | +10.48% | +38.11% |
05-22 | Sandoz: Marketing authorization for Wyost and Jubbonti in the EU | CF |
05-22 | Roche Gets US FDA Breakthrough Designation For Lipoprotein(a) Test | MT |
Sales 2024 * | 33B 29,387B 2,595B | Sales 2025 * | 33.96B 30,245B 2,671B | Capitalization | 166B 147,804B 13,052B |
---|---|---|---|---|---|
Net income 2024 * | 4.13B 3,680B 325B | Net income 2025 * | 6.61B 5,887B 520B | EV / Sales 2024 * | 6.5 x |
Net Debt 2024 * | 48.46B 43,150B 3,810B | Net Debt 2025 * | 43.54B 38,775B 3,424B | EV / Sales 2025 * | 6.17 x |
P/E ratio 2024 * |
38.9
x | P/E ratio 2025 * |
24.7
x | Employees | 26,700 |
Yield 2024 * |
2.98% | Yield 2025 * |
3.23% | Free-Float | 99.75% |
Latest transcript on Amgen Inc.
1 day | +2.77% | ||
1 week | +10.48% | ||
Current month | +28.94% | ||
1 month | +34.14% | ||
3 months | +23.48% | ||
6 months | +57.67% | ||
Current year | +38.11% |
Managers | Title | Age | Since |
---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 61 | 31/05/06 |
Peter Griffith
DFI | Director of Finance/CFO | 65 | 22/10/19 |
James Bradner
CTO | Chief Tech/Sci/R&D Officer | 52 | 12-17 |
Members of the board | Title | Age | Since |
---|---|---|---|
Charles Holley
BRD | Director/Board Member | 67 | 02/02/17 |
Ellen Kullman
BRD | Director/Board Member | 68 | 13/10/16 |
Robert Williams
BRD | Director/Board Member | 75 | 16/10/14 |
Date | Price | Change | Volume |
---|---|---|---|
22/05/24 | 12,890 | +2.77% | 817 |
21/05/24 | 12,542 | +5.26% | 842 |
20/05/24 | 11,916 | +3.60% | 590 |
17/05/24 | 11,502 | +0.02% | 656 |
16/05/24 | 11,499 | -1.45% | 1,091 |
End-of-day quote Buenos Aires S.E., May 21, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+40.01% | 723B | |
+34.28% | 595B | |
-3.76% | 369B | |
+20.38% | 332B | |
+3.16% | 282B | |
+17.02% | 244B | |
+9.31% | 208B | |
-5.07% | 205B | |
+0.24% | 168B |
- Stock Market
- Equities
- AMGN Stock
- AMGN Stock